接受联合抗逆转录病毒疗法或蛋白酶抑制剂单一疗法的HIV感染儿童在免疫激活和微生物易位方面没有差异。
No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy.
作者信息
Falcon-Neyra Lola, Benmarzouk-Hidalgo Omar J, Madrid Lola, Noguera-Julian Antoni, Fortuny Claudia, Neth Olaf, López-Cortés Luis
机构信息
From the Unidad de Enfermedades Infecciosas e Inmunopatologias, Hospital Infantil Virgen del Rocio, Instituto de Biomedicina de Sevilla (LF-N, LM, ON); Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Sevilla (OJB-H, LL-C); ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; and Unitat d'Infectologia, Servei de Pediatria, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain (LM, AN-J, CF).
出版信息
Medicine (Baltimore). 2015 Mar;94(11):e521. doi: 10.1097/MD.0000000000000521.
This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretroviral treatment (cART; n = 10) or ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv; n = 5). In both cases, IA and MT were lower in healthy control children (n = 32). This observational study suggests that ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not associated with an increased state of IA or MT as compared with children receiving cART.
这是一项针对15名无病毒血症的慢性HIV感染儿童的横断面研究，结果显示，接受联合抗逆转录病毒治疗（cART；n = 10）或利托那韦增强蛋白酶抑制剂单药治疗（mtPI/rtv；n = 5）的HIV感染患者在免疫激活（IA；HLA-DR⁺CD38⁺CD4和CD8 T细胞，以及sCD14）和微生物易位（MT；脂多糖（LPS）和16S rDNA）方面没有差异。在这两种情况下，健康对照儿童（n = 32）的IA和MT水平较低。这项观察性研究表明，与接受cART的儿童相比，利托那韦增强蛋白酶抑制剂单药治疗（mtPI/rtv）与IA或MT状态增加无关。
Zotero 插件